首页 > 最新文献

Cancer Cell最新文献

英文 中文
Turn CAR T against TAMs. 让CAR - T对抗tam。
IF 44.5 1区 医学 Q1 CELL BIOLOGY Pub Date : 2026-02-05 DOI: 10.1016/j.ccell.2026.01.008
Alberto Mantovani, Cecilia Garlanda

The diversity of tumor-associated macrophages presents a major challenge to the clinical translation of myeloid cell-targeting strategies. In this issue of Cancer Cell, Yagel et al. and Mateus-Tique et al. demonstrate that IL-12 armored CAR T cells effectively target tumor-promoting macrophage populations and reset the microenvironment toward an anti-cancer mode.

肿瘤相关巨噬细胞的多样性对髓细胞靶向策略的临床翻译提出了重大挑战。在本期的《Cancer Cell》中,Yagel等人和Mateus-Tique等人证明了IL-12装甲CAR -T细胞有效地靶向促肿瘤巨噬细胞群,并将微环境重置为抗癌模式。
{"title":"Turn CAR T against TAMs.","authors":"Alberto Mantovani, Cecilia Garlanda","doi":"10.1016/j.ccell.2026.01.008","DOIUrl":"https://doi.org/10.1016/j.ccell.2026.01.008","url":null,"abstract":"<p><p>The diversity of tumor-associated macrophages presents a major challenge to the clinical translation of myeloid cell-targeting strategies. In this issue of Cancer Cell, Yagel et al. and Mateus-Tique et al. demonstrate that IL-12 armored CAR T cells effectively target tumor-promoting macrophage populations and reset the microenvironment toward an anti-cancer mode.</p>","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":" ","pages":""},"PeriodicalIF":44.5,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146131308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Male-biased Yap1-Cd276/B7-H3 axis for immune evasion in medulloblastoma. 男性偏倚的Yap1-Cd276/B7-H3轴在成神经管细胞瘤中的免疫逃避。
IF 44.5 1区 医学 Q1 CELL BIOLOGY Pub Date : 2026-02-05 DOI: 10.1016/j.ccell.2026.01.005
Nourhan Abdelfattah, Sivaraman Natarajan, Han Nhat Tran, Thomas Wong, Maryam Faisal, Jose Maldonado, Rachael McMinimy, Hannah Borland, Shu-Hsia Chen, Hong Zhao, Matthew Vasquez, Freddys F Rodriguez, Carston R Wagner, Fernando Camargo, James Olson, Joshy George, Kyuson Yun

Molecular mechanisms underlying sex-specific differences in cancer incidence and therapy responses are under intense investigation. Here, we report sex-biased functions of Yap1 in multiple cancer types in human and mouse. Through integrated multi-omics analyses, we demonstrate that Yap1 deletion significantly extends survival in male but not female Sonic Hedgehog (SHH) medulloblastomas (MB) models. While Yap1 is required to maintain stem-like cells in both sexes, Yap1 plays a more critical role in immune evasion in males. Mechanistically, YAP1 is essential for activating Cd276/B7-H3 expression to mediate CD8+ T cell suppression in males. Consistently, CD276 inhibition extends survival in male but not female SHH MB. Moreover, in vivo targets of YAP1 stratify survival in male but not female patients with medulloblastoma, glioblastoma, mesothelioma, and lung cancer. This study provides evidence for sex-biased functions of Yap1 and CD276 in MB immune suppression and highlights the importance of biological sex in cancer:immune interactions.

癌症发病率和治疗反应的性别差异背后的分子机制正在深入研究中。在这里,我们报道了Yap1在人类和小鼠多种癌症类型中的性别偏倚功能。通过综合多组学分析,我们证明Yap1缺失显著延长了男性而非女性Sonic Hedgehog (SHH)髓母细胞瘤(MB)模型的生存期。虽然Yap1在两性中都需要维持干细胞样细胞,但在男性的免疫逃避中,Yap1起着更关键的作用。在机制上,YAP1是激活Cd276/B7-H3表达介导CD8+ T细胞抑制的必要条件。一致地,CD276抑制延长了男性而非女性SHH MB的生存期。此外,YAP1的体内靶点在髓母细胞瘤、胶质母细胞瘤、间皮瘤和肺癌的男性患者中分层生存,而在女性患者中分层生存。这项研究为Yap1和CD276在MB免疫抑制中的性别偏向功能提供了证据,并强调了生物学性别在癌症免疫相互作用中的重要性。
{"title":"Male-biased Yap1-Cd276/B7-H3 axis for immune evasion in medulloblastoma.","authors":"Nourhan Abdelfattah, Sivaraman Natarajan, Han Nhat Tran, Thomas Wong, Maryam Faisal, Jose Maldonado, Rachael McMinimy, Hannah Borland, Shu-Hsia Chen, Hong Zhao, Matthew Vasquez, Freddys F Rodriguez, Carston R Wagner, Fernando Camargo, James Olson, Joshy George, Kyuson Yun","doi":"10.1016/j.ccell.2026.01.005","DOIUrl":"https://doi.org/10.1016/j.ccell.2026.01.005","url":null,"abstract":"<p><p>Molecular mechanisms underlying sex-specific differences in cancer incidence and therapy responses are under intense investigation. Here, we report sex-biased functions of Yap1 in multiple cancer types in human and mouse. Through integrated multi-omics analyses, we demonstrate that Yap1 deletion significantly extends survival in male but not female Sonic Hedgehog (SHH) medulloblastomas (MB) models. While Yap1 is required to maintain stem-like cells in both sexes, Yap1 plays a more critical role in immune evasion in males. Mechanistically, YAP1 is essential for activating Cd276/B7-H3 expression to mediate CD8<sup>+</sup> T cell suppression in males. Consistently, CD276 inhibition extends survival in male but not female SHH MB. Moreover, in vivo targets of YAP1 stratify survival in male but not female patients with medulloblastoma, glioblastoma, mesothelioma, and lung cancer. This study provides evidence for sex-biased functions of Yap1 and CD276 in MB immune suppression and highlights the importance of biological sex in cancer:immune interactions.</p>","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":" ","pages":""},"PeriodicalIF":44.5,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146131376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reliable detection of Host-Microbe Signatures in cancer using PRISM. 利用PRISM可靠地检测癌症宿主-微生物特征。
IF 44.5 1区 医学 Q1 CELL BIOLOGY Pub Date : 2026-02-05 DOI: 10.1016/j.ccell.2026.01.007
Bassel Ghaddar, Martin J Blaser, Subhajyoti De

Recent controversy in the cancer microbiome field highlights the need for more reliable microbial detection from human genomic data. Here, we develop PRISM, an efficient computational framework for precise microorganism identification and decontamination from low-biomass sequencing data. PRISM achieves robust performance when benchmarked on 230 independent datasets with known true-positive and contaminant taxa. We then use PRISM to profile 25 cancer types from The Cancer Genome Atlas and Clinical Proteomic Tumor Analysis Consortium. We identify consistent microbial signatures in gastrointestinal tract, head-and-neck, and urogenital tract tumors, and sparse signal elsewhere. In pancreatic cancer, we associate microbial detection with altered host protein glycosylation pathways and greater smoking exposure. Lastly, we consider the impact of sequencing approaches on positive and negative data interpretation. Overall, PRISM improves the reliability of microbial profiling and allows leveraging of existing human genomic data for the concurrent detection of host-microbial signatures with potential molecular and clinical significance.

最近在癌症微生物组领域的争议强调了从人类基因组数据中进行更可靠的微生物检测的必要性。在这里,我们开发了PRISM,这是一个有效的计算框架,用于精确的微生物鉴定和从低生物量测序数据中去除污染。PRISM在230个具有已知真阳性和污染分类群的独立数据集上进行基准测试时实现了稳健的性能。然后,我们使用PRISM分析来自癌症基因组图谱和临床蛋白质组学肿瘤分析联盟的25种癌症类型。我们在胃肠道、头颈部和泌尿生殖道肿瘤中发现了一致的微生物特征,而在其他地方发现了稀疏的信号。在胰腺癌中,我们将微生物检测与宿主蛋白糖基化途径的改变和更大的吸烟暴露联系起来。最后,我们考虑了测序方法对正面和负面数据解释的影响。总体而言,PRISM提高了微生物谱分析的可靠性,并允许利用现有的人类基因组数据同时检测具有潜在分子和临床意义的宿主-微生物特征。
{"title":"Reliable detection of Host-Microbe Signatures in cancer using PRISM.","authors":"Bassel Ghaddar, Martin J Blaser, Subhajyoti De","doi":"10.1016/j.ccell.2026.01.007","DOIUrl":"https://doi.org/10.1016/j.ccell.2026.01.007","url":null,"abstract":"<p><p>Recent controversy in the cancer microbiome field highlights the need for more reliable microbial detection from human genomic data. Here, we develop PRISM, an efficient computational framework for precise microorganism identification and decontamination from low-biomass sequencing data. PRISM achieves robust performance when benchmarked on 230 independent datasets with known true-positive and contaminant taxa. We then use PRISM to profile 25 cancer types from The Cancer Genome Atlas and Clinical Proteomic Tumor Analysis Consortium. We identify consistent microbial signatures in gastrointestinal tract, head-and-neck, and urogenital tract tumors, and sparse signal elsewhere. In pancreatic cancer, we associate microbial detection with altered host protein glycosylation pathways and greater smoking exposure. Lastly, we consider the impact of sequencing approaches on positive and negative data interpretation. Overall, PRISM improves the reliability of microbial profiling and allows leveraging of existing human genomic data for the concurrent detection of host-microbial signatures with potential molecular and clinical significance.</p>","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":" ","pages":""},"PeriodicalIF":44.5,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146131390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CCL3 is produced by aged neutrophils across cancers and promotes tumor growth. CCL3是由衰老的中性粒细胞在癌症中产生并促进肿瘤生长。
IF 44.5 1区 医学 Q1 CELL BIOLOGY Pub Date : 2026-02-05 DOI: 10.1016/j.ccell.2026.01.006
Evangelia Bolli, Pratyaksha Wirapati, Mehdi Hicham, Yuxuan Xie, Marie Siwicki, Florent Duval, Anne-Gaëlle Goubet, Máté Kiss, Béatrice Zitti, Thomas Zwahlen, Sheri Mcdowell, Ruben Bill, Simona Angerani, Camilla Engblom, Seth Anderson, Aiping Jiang, Oliver Hartley, David B Sykes, Maja Jankovic, Nadine Fournier, Matthias Gunzer, David Tarussio, Stéphanie Tissot, Peter M Sadow, William C Faquin, Moshe Sade-Feldman, Ralph Weissleder, Sara Pai, François Mercier, Robert Manguso, Mikaël J Pittet

Tumor-associated neutrophils (TANs) are abundant across cancers, yet their phenotypic diversity and functional states remain poorly defined. Here, we introduce a cell-type probability classifier that recovers low-transcript neutrophils from scRNAseq datasets, enabling pan-cancer analyses of TAN heterogeneity. Across >190 human and murine tumors, we identify a conserved differentiation trajectory that culminates in a terminal CCL3hi state. This state exhibits pro-tumor transcriptional programs, including those involved in hypoxic adaptation and senescence. Consistently, CCL3hi TANs are enriched in hypoxic tumor niches in both humans and mice. Through mechanistic perturbations of neutrophil-derived CCL3 in mice, we show that it sustains TAN survival in hypoxic tumor regions via CCR1-dependent signaling. These findings establish CCL3 as a conserved marker and functional driver of pro-tumor neutrophils in growing tumors, and provide a scalable framework for dissecting neutrophil biology across cancer types.

肿瘤相关中性粒细胞(TANs)在癌症中丰富,但其表型多样性和功能状态仍不明确。在这里,我们引入了一种细胞类型概率分类器,可以从scRNAseq数据集中恢复低转录中性粒细胞,从而实现对TAN异质性的泛癌症分析。在bbbb190人类和小鼠肿瘤中,我们发现了一个保守的分化轨迹,最终达到了终末期CCL3hi状态。这种状态表现出促肿瘤转录程序,包括那些参与缺氧适应和衰老的转录程序。一致地,CCL3hi TANs在人类和小鼠的缺氧肿瘤壁龛中富集。通过对小鼠中性粒细胞来源的CCL3的机制扰动,我们发现它通过ccr1依赖的信号传导维持缺氧肿瘤区域的TAN存活。这些发现证实了CCL3在肿瘤生长过程中是一种保守的标记物和促瘤中性粒细胞的功能驱动因子,并为解剖不同类型肿瘤的中性粒细胞生物学提供了一个可扩展的框架。
{"title":"CCL3 is produced by aged neutrophils across cancers and promotes tumor growth.","authors":"Evangelia Bolli, Pratyaksha Wirapati, Mehdi Hicham, Yuxuan Xie, Marie Siwicki, Florent Duval, Anne-Gaëlle Goubet, Máté Kiss, Béatrice Zitti, Thomas Zwahlen, Sheri Mcdowell, Ruben Bill, Simona Angerani, Camilla Engblom, Seth Anderson, Aiping Jiang, Oliver Hartley, David B Sykes, Maja Jankovic, Nadine Fournier, Matthias Gunzer, David Tarussio, Stéphanie Tissot, Peter M Sadow, William C Faquin, Moshe Sade-Feldman, Ralph Weissleder, Sara Pai, François Mercier, Robert Manguso, Mikaël J Pittet","doi":"10.1016/j.ccell.2026.01.006","DOIUrl":"https://doi.org/10.1016/j.ccell.2026.01.006","url":null,"abstract":"<p><p>Tumor-associated neutrophils (TANs) are abundant across cancers, yet their phenotypic diversity and functional states remain poorly defined. Here, we introduce a cell-type probability classifier that recovers low-transcript neutrophils from scRNAseq datasets, enabling pan-cancer analyses of TAN heterogeneity. Across >190 human and murine tumors, we identify a conserved differentiation trajectory that culminates in a terminal CCL3<sup>hi</sup> state. This state exhibits pro-tumor transcriptional programs, including those involved in hypoxic adaptation and senescence. Consistently, CCL3<sup>hi</sup> TANs are enriched in hypoxic tumor niches in both humans and mice. Through mechanistic perturbations of neutrophil-derived CCL3 in mice, we show that it sustains TAN survival in hypoxic tumor regions via CCR1-dependent signaling. These findings establish CCL3 as a conserved marker and functional driver of pro-tumor neutrophils in growing tumors, and provide a scalable framework for dissecting neutrophil biology across cancer types.</p>","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":" ","pages":""},"PeriodicalIF":44.5,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146131395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Kupffer Cell-Derived Tnf Triggers Cholangiocellular Tumorigenesis through JNK due to Chronic Mitochondrial Dysfunction and ROS Kupffer细胞来源的Tnf通过JNK触发慢性线粒体功能障碍和ROS引起的胆管细胞肿瘤发生
IF 50.3 1区 医学 Q1 CELL BIOLOGY Pub Date : 2026-01-31 DOI: 10.1016/j.ccell.2026.01.013
Detian Yuan, Shan Huang, Emanuel Berger, Lei Liu, Nina Gross, Florian Heinzmann, Marc Ringelhan, Tracy O. Connor, Mira Stadler, Michael Meister, Julia Weber, Rupert Öllinger, Nicole Simonavicius, Florian Reisinger, Daniel Hartmann, Rüdiger Meyer, Maria Reich, Marco Seehawer, Valentina Leone, Bastian Höchst, Dirk Wohlleber, Simone Jörs, Marco Prinz, Duncan Spalding, Ulrike Protzer, Tom Luedde, Luigi Terracciano, Matthias Matter, Thomas Longerich, Percy Knolle, Thomas Ried, Verena Keitel, Fabian Geisler, Kristian Unger, Einat Cinnamon, Eli Pikarsky, Norbert Hüser, Roger J. Davis, Darjus F. Tschaharganeh, Roland Rad, Achim Weber, Lars Zender, Dirk Haller, Mathias Heikenwalder
{"title":"Kupffer Cell-Derived Tnf Triggers Cholangiocellular Tumorigenesis through JNK due to Chronic Mitochondrial Dysfunction and ROS","authors":"Detian Yuan, Shan Huang, Emanuel Berger, Lei Liu, Nina Gross, Florian Heinzmann, Marc Ringelhan, Tracy O. Connor, Mira Stadler, Michael Meister, Julia Weber, Rupert Öllinger, Nicole Simonavicius, Florian Reisinger, Daniel Hartmann, Rüdiger Meyer, Maria Reich, Marco Seehawer, Valentina Leone, Bastian Höchst, Dirk Wohlleber, Simone Jörs, Marco Prinz, Duncan Spalding, Ulrike Protzer, Tom Luedde, Luigi Terracciano, Matthias Matter, Thomas Longerich, Percy Knolle, Thomas Ried, Verena Keitel, Fabian Geisler, Kristian Unger, Einat Cinnamon, Eli Pikarsky, Norbert Hüser, Roger J. Davis, Darjus F. Tschaharganeh, Roland Rad, Achim Weber, Lars Zender, Dirk Haller, Mathias Heikenwalder","doi":"10.1016/j.ccell.2026.01.013","DOIUrl":"https://doi.org/10.1016/j.ccell.2026.01.013","url":null,"abstract":"","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"74 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2026-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146095769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors p53是smarcb1缺陷型恶性横纹肌样肿瘤中蛋白抑制的主要调控因子
IF 50.3 1区 医学 Q1 CELL BIOLOGY Pub Date : 2026-01-31 DOI: 10.1016/j.ccell.2026.01.018
Alessandro Carugo, Rosalba Minelli, Luigi Sapio, Melinda Soeung, Federica Carbone, Frederick S. Robinson, James Tepper, Ziheng Chen, Sara Lovisa, Maria Svelto, Samirkumar Amin, Sanjana Srinivasan, Edoardo Del Poggetto, Sara Loponte, Francesca Puca, Prasenjit Dey, Gabriel G. Malouf, Xiaoping Su, Liren Li, Dolores Lopez-Terrada, Dinesh Rakheja, Alexander J. Lazar, George J. Netto, Priya Rao, Alessandro Sgambato, Anirban Maitra, Durga N. Tripathi, Cheryl L. Walker, Jose A. Karam, Timothy P. Heffernan, Andrea Viale, Charles W.M. Roberts, Pavlos Msaouel, Nizar M. Tannir, Giulio F. Draetta, Giannicola Genovese
{"title":"p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors","authors":"Alessandro Carugo, Rosalba Minelli, Luigi Sapio, Melinda Soeung, Federica Carbone, Frederick S. Robinson, James Tepper, Ziheng Chen, Sara Lovisa, Maria Svelto, Samirkumar Amin, Sanjana Srinivasan, Edoardo Del Poggetto, Sara Loponte, Francesca Puca, Prasenjit Dey, Gabriel G. Malouf, Xiaoping Su, Liren Li, Dolores Lopez-Terrada, Dinesh Rakheja, Alexander J. Lazar, George J. Netto, Priya Rao, Alessandro Sgambato, Anirban Maitra, Durga N. Tripathi, Cheryl L. Walker, Jose A. Karam, Timothy P. Heffernan, Andrea Viale, Charles W.M. Roberts, Pavlos Msaouel, Nizar M. Tannir, Giulio F. Draetta, Giannicola Genovese","doi":"10.1016/j.ccell.2026.01.018","DOIUrl":"https://doi.org/10.1016/j.ccell.2026.01.018","url":null,"abstract":"","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"381 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2026-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146095768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lymph node colonization induces tissue remodeling via immunosuppressive fibroblast-myeloid cell niches supporting metastatic tolerance 淋巴结定植通过支持转移耐受的免疫抑制成纤维细胞-骨髓细胞龛诱导组织重塑
IF 50.3 1区 医学 Q1 CELL BIOLOGY Pub Date : 2026-01-29 DOI: 10.1016/j.ccell.2026.01.003
Maximilian Haist, Marc-A. Baertsch, Nathan E. Reticker-Flynn, Guolan Lu, Tim N. Kempchen, Pauline Chu, Gustavo Vazquez, Han Chen, John B. Sunwoo, Weiruo Zhang, Eyiwunmi Laseinde, Bonny Adami, Stefanie Zimmer, Justus Kaufman, Quynh Thu Le, Andrew J. Gentles, Christina S. Kong, Sylvia K. Plevritis, Yury Goltsev, John W. Hickey, Garry P. Nolan
{"title":"Lymph node colonization induces tissue remodeling via immunosuppressive fibroblast-myeloid cell niches supporting metastatic tolerance","authors":"Maximilian Haist, Marc-A. Baertsch, Nathan E. Reticker-Flynn, Guolan Lu, Tim N. Kempchen, Pauline Chu, Gustavo Vazquez, Han Chen, John B. Sunwoo, Weiruo Zhang, Eyiwunmi Laseinde, Bonny Adami, Stefanie Zimmer, Justus Kaufman, Quynh Thu Le, Andrew J. Gentles, Christina S. Kong, Sylvia K. Plevritis, Yury Goltsev, John W. Hickey, Garry P. Nolan","doi":"10.1016/j.ccell.2026.01.003","DOIUrl":"https://doi.org/10.1016/j.ccell.2026.01.003","url":null,"abstract":"","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"7 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146071526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AI for cancer treatment information: Can academia stay in the game? 癌症治疗信息的人工智能:学术界能继续参与吗?
IF 50.3 1区 医学 Q1 CELL BIOLOGY Pub Date : 2026-01-29 DOI: 10.1016/j.ccell.2026.01.002
Justin Jee, Travis Zack
{"title":"AI for cancer treatment information: Can academia stay in the game?","authors":"Justin Jee, Travis Zack","doi":"10.1016/j.ccell.2026.01.002","DOIUrl":"https://doi.org/10.1016/j.ccell.2026.01.002","url":null,"abstract":"","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"8 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146072066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emerging landscape of KRAS inhibitors in cancer treatment KRAS抑制剂在癌症治疗中的新前景
IF 50.3 1区 医学 Q1 CELL BIOLOGY Pub Date : 2026-01-29 DOI: 10.1016/j.ccell.2026.01.001
Jakob M. Riedl, Hiroyuki Matsubara, Reid McNeil, Parasvi S. Patel, Ferran Fece de la Cruz, Doga C. Gulhan, Ryan B. Corcoran
Alterations in KRAS, NRAS, and HRAS occur in roughly 20% of patients with cancer, making RAS one of the most intensively studied oncogenic targets. The discovery of mutant-selective KRASG12C inhibitors has provided a proof-of-concept for RAS-directed therapies, heralding a new era in the treatment of RAS-driven cancers. Yet, the efficacy of first-generation KRASG12C inhibitors is limited by the rapid emergence of resistance. Novel classes of (K)RAS inhibitors with distinct mechanisms of action and broader target coverage hold promise to overcome resistance and extend the benefits of RAS-targeted therapies to a wider patient population. In this review, we summarize clinical evidence for KRASG12C inhibitors across tumor types and delineate key mechanisms of resistance. We further discuss the rapidly evolving landscape of next-generation (K)RAS inhibitors, with particular emphasis on their target selectivity, mechanisms of action, preliminary clinical efficacy, and the therapeutic opportunities and challenges inherent to each class.
大约20%的癌症患者发生KRAS、NRAS和HRAS的改变,使RAS成为研究最深入的致癌靶点之一。突变选择性KRASG12C抑制剂的发现为ras定向治疗提供了概念验证,预示着ras驱动型癌症治疗的新时代。然而,第一代KRASG12C抑制剂的疗效受到耐药性快速出现的限制。具有不同作用机制和更广泛靶点覆盖的新型(K)RAS抑制剂有望克服耐药性,并将RAS靶向治疗的益处扩展到更广泛的患者群体。在这篇综述中,我们总结了KRASG12C抑制剂在不同肿瘤类型中的临床证据,并描述了耐药的关键机制。我们进一步讨论了下一代(K)RAS抑制剂的快速发展前景,特别强调它们的靶点选择性,作用机制,初步临床疗效,以及每一类固有的治疗机会和挑战。
{"title":"Emerging landscape of KRAS inhibitors in cancer treatment","authors":"Jakob M. Riedl, Hiroyuki Matsubara, Reid McNeil, Parasvi S. Patel, Ferran Fece de la Cruz, Doga C. Gulhan, Ryan B. Corcoran","doi":"10.1016/j.ccell.2026.01.001","DOIUrl":"https://doi.org/10.1016/j.ccell.2026.01.001","url":null,"abstract":"Alterations in <em>KRAS</em>, <em>NRAS</em>, and <em>HRAS</em> occur in roughly 20% of patients with cancer, making RAS one of the most intensively studied oncogenic targets. The discovery of mutant-selective KRAS<sup>G12C</sup> inhibitors has provided a proof-of-concept for RAS-directed therapies, heralding a new era in the treatment of RAS-driven cancers. Yet, the efficacy of first-generation KRAS<sup>G12C</sup> inhibitors is limited by the rapid emergence of resistance. Novel classes of (K)RAS inhibitors with distinct mechanisms of action and broader target coverage hold promise to overcome resistance and extend the benefits of RAS-targeted therapies to a wider patient population. In this review, we summarize clinical evidence for KRAS<sup>G12C</sup> inhibitors across tumor types and delineate key mechanisms of resistance. We further discuss the rapidly evolving landscape of next-generation (K)RAS inhibitors, with particular emphasis on their target selectivity, mechanisms of action, preliminary clinical efficacy, and the therapeutic opportunities and challenges inherent to each class.","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"54 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146070575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tumor-antigen-independent targeting of solid tumors by armored macrophage-directed anti-TREM2 CAR T cells 装甲巨噬细胞靶向抗trem2 CAR -T细胞对实体肿瘤的非肿瘤抗原靶向作用
IF 50.3 1区 医学 Q1 CELL BIOLOGY Pub Date : 2026-01-22 DOI: 10.1016/j.ccell.2025.11.009
Gal Yagel, Dana Rimini, Michelle von Locquenghien, Roberto Avellino, Oren Barboy, Paulina Chalan, Gaya Granot, Ken Xie, Shir Shlomi-Loubaton, Fadi Sheban, Kfir Mazuz, Eyal David, Pascale Zwicky, Ido Amit
Chimeric antigen receptor (CAR) T cell therapy has shown remarkable success in hematologic malignancies and autoimmune diseases but remains limited in solid tumors due to antigen heterogeneity, escape, and an immunosuppressive tumor microenvironment (TME) dominated by tumor-associated macrophages (TAMs). We developed a macrophage-directed CAR T strategy targeting TREM2+ immunosuppressive TAMs, achieving potent in vitro activity and robust antitumor efficacy in vivo. To enhance intratumoral activity, we incorporated synthetic CAR-responsive biosensors containing NFAT, IRF, and AP1 motifs that enable localized IL-12 secretion upon activation. In an immunocompetent human TREM2 transgenic murine model, IL-12-armored hTREM2 CAR T cells remodel the TME and tumor-draining lymph nodes, depleting TREM2+ TAMs, enhancing T and natural killer (NK) cell infiltration and activation, and inducing tumor regression without systemic toxicity. This study highlights the potential for developing universal and efficacious CAR T cell therapies targeting tumor-associated macrophages for the treatment of solid tumors.
嵌合抗原受体(CAR) T细胞治疗在血液恶性肿瘤和自身免疫性疾病中显示出显著的成功,但由于抗原异质性、逃逸和由肿瘤相关巨噬细胞(tam)主导的免疫抑制肿瘤微环境(TME),在实体肿瘤中仍然受到限制。我们开发了一种针对TREM2+免疫抑制tam的巨噬细胞定向CAR - T策略,获得了强大的体外活性和体内抗肿瘤功效。为了增强肿瘤内活性,我们合成了含有NFAT、IRF和AP1基元的car响应生物传感器,这些基元能够在激活时局部分泌IL-12。在免疫能力强的人TREM2转基因小鼠模型中,il -12装甲hTREM2 CAR - T细胞重塑TME和肿瘤引流淋巴结,消耗TREM2+ tam,增强T细胞和自然杀伤细胞(NK)的浸润和活化,诱导肿瘤消退,无全身毒性。这项研究强调了开发针对肿瘤相关巨噬细胞的通用和有效的CAR - T细胞疗法治疗实体瘤的潜力。
{"title":"Tumor-antigen-independent targeting of solid tumors by armored macrophage-directed anti-TREM2 CAR T cells","authors":"Gal Yagel, Dana Rimini, Michelle von Locquenghien, Roberto Avellino, Oren Barboy, Paulina Chalan, Gaya Granot, Ken Xie, Shir Shlomi-Loubaton, Fadi Sheban, Kfir Mazuz, Eyal David, Pascale Zwicky, Ido Amit","doi":"10.1016/j.ccell.2025.11.009","DOIUrl":"https://doi.org/10.1016/j.ccell.2025.11.009","url":null,"abstract":"Chimeric antigen receptor (CAR) T cell therapy has shown remarkable success in hematologic malignancies and autoimmune diseases but remains limited in solid tumors due to antigen heterogeneity, escape, and an immunosuppressive tumor microenvironment (TME) dominated by tumor-associated macrophages (TAMs). We developed a macrophage-directed CAR T strategy targeting TREM2<sup>+</sup> immunosuppressive TAMs, achieving potent <em>in vitro</em> activity and robust antitumor efficacy <em>in vivo</em>. To enhance intratumoral activity, we incorporated synthetic CAR-responsive biosensors containing NFAT, IRF, and AP1 motifs that enable localized IL-12 secretion upon activation. In an immunocompetent human TREM2 transgenic murine model, IL-12-armored hTREM2 CAR T cells remodel the TME and tumor-draining lymph nodes, depleting TREM2<sup>+</sup> TAMs, enhancing T and natural killer (NK) cell infiltration and activation, and inducing tumor regression without systemic toxicity. This study highlights the potential for developing universal and efficacious CAR T cell therapies targeting tumor-associated macrophages for the treatment of solid tumors.","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"16 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146022168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cancer Cell
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1